A
Alcista
Alcista · 25%IONS
$34.91
Precio del escenario
$45.400
+1.044 (+2.30%)Al cierre
Loading chart…
- Máximo
- 45.480
- Apertura
- 44.450
- Precio medio ponderado por volumen
- 44.96
- Volumen
- 2.49M
- Capitalización
- 6.89B
- Mínimo
- 44.010
- Importe
- 111.84M
- EV/EBITDA, TTM
- -18.48
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Análisis de IA of Ionis Pharmaceuticals Inc (IONS)
MantenerIonis Pharmaceuticals is currently not a strong buy. The stock is trading at $42.94, which is significantly below its 200-day simple moving average of $68.60, indicating a bearish trend. Additionally, the RSI is at 41.83, suggesting that the stock is nearing oversold territory but not yet a clear buy signal. The forward P/E ratio is extremely high at 90.91, indicating that the stock may be overvalued based on future earnings expectations. Furthermore, the company reported a significant year-to-date decline of 46.10%, which raises concerns about its short-term performance. The main risk is the recent negative sentiment reflected in analyst downgrades and competitive pressures, particularly from Alnylam, which reported a 41% revenue decline for Ionis compared to its own 74% growth.
Recomendaciones de analistas (15)
+104.12% de potencial alcista
Mantener
5 Comprar
8 Mantener
2 Vender
Actual: 45.40
Mínimo
65.00
Promedio
92.67
Máximo
110.00
JPMorgan
Sobreponderar
$70
2026-09-22
JPMorgan
2026-09-22
Precio objetivo
$70
Sobreponderar
Guggenheim
Comprar
$80
2026-09-15
Guggenheim
2026-09-15
Precio objetivo
$80
Comprar
Barclays
Sobreponderar
$85
2026-09-09
Barclays
2026-09-09
Precio objetivo
$85
Sobreponderar
Raymond James
Superar al mercado
$84
2026-09-08
Raymond James
2026-09-08
Precio objetivo
$84
Superar al mercado
Morgan Stanley
Sobreponderar
$104
2026-09-08
Morgan Stanley
2026-09-08
Precio objetivo
$104
Sobreponderar
Métricas de valoración
El PER previsto actual de Ionis Pharmaceuticals Inc (IONS) es 90.91, frente a su media de 5 años de 1.06.
Escenarios de precio de Alphio AI para IONS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IONS en cartera
Cronología de eventos
Noticias
9.010-21NewsfilterFDA Approves Hibsago for Chronic Hepatitis B Treatment
- 8.510-16Newsfilter
Ionis Pharmaceuticals Receives Positive CHMP Opinion for TRYNGOLZA in EU
9.510-10FoolFinancial Comparison of Alnylam and Ionis
9.509-28FoolAlnylam Pharmaceuticals Stock Rises 25% but Still Down 35% Year-to-Date
9.009-23NASDAQ.COMRoche Reports Positive Interim Results for IgA Nephropathy Treatment
Preguntas frecuentes sobre IONS, respondidas por Alphio AI
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ionis Pharmaceuticals is currently not a strong buy. The stock is trading at $42.94, which is significantly below its 200-day simple moving average of $68.60, indicating a bearish trend. Additionally, the RSI is at 41.83, suggesting that the stock is nearing oversold territory but not yet a clear buy signal. The forward P/E ratio is extremely high at 90.91, indicating that the stock may be overvalued based on future earnings expectations. Furthermore, the company reported a significant year-to-date decline of 46.10%, which raises concerns about its short-term performance. The main risk is the recent negative sentiment reflected in analyst downgrades and competitive pressures, particularly from Alnylam, which reported a 41% revenue decline for Ionis compared to its own 74% growth.
15 analysts cover IONS: 5 rate it Buy, 8 Hold and 2 Sell. The average price target is 92.67.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.